Marinomed Biotech AG, Korneuburg, Austria.
Institute of Virology, Friedrich-Alexander University Erlangen-Nürnberg (FAU), Erlangen, Germany.
PLoS One. 2021 Feb 17;16(2):e0237480. doi: 10.1371/journal.pone.0237480. eCollection 2021.
In the absence of a vaccine and other effective prophylactic or therapeutic countermeasures the severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) remains a significant public health threat. Attachment and entry of coronaviruses including SARS-CoV-2 is mainly mediated by the spike glycoprotein. Here, we show that iota-carrageenan can inhibit the cell entry of the SARS-CoV-2 spike pseudotyped lentivirus in a dose dependent manner. SARS-CoV-2 spike pseudotyped lentivirus particles were efficiently neutralized with an IC50 value of 2.6 μg/ml iota-carrageenan. Experiments with patient isolated wild type SARS-CoV-2 virus showed an inhibition of replication in a similar range. In vitro data on iota-carrageenan against various Rhino- and endemic Coronaviruses showed similar IC50 values and translated readily into clinical effectiveness when a nasal spray containing iota-carrageenan demonstrated a reduction of severity and duration of symptoms of common cold caused by various respiratory viruses. Accordingly, our in vitro data on SARS-CoV-2 spike pseudotyped lentivirus and replication competent SARS-CoV-2 suggest that administration of iota-carrageenan may be an effective and safe prophylaxis or treatment for SARS-CoV-2 infections.
在没有疫苗和其他有效预防或治疗对策的情况下,严重急性呼吸系统综合征相关冠状病毒 2(SARS-CoV-2)仍然是一个重大的公共卫生威胁。包括 SARS-CoV-2 在内的冠状病毒的附着和进入主要是由刺突糖蛋白介导的。在这里,我们表明iota-卡拉胶可以剂量依赖的方式抑制 SARS-CoV-2 刺突假型慢病毒的细胞进入。SARS-CoV-2 刺突假型慢病毒颗粒被 iota-卡拉胶以 2.6 μg/ml 的 IC50 值有效中和。用患者分离的野生型 SARS-CoV-2 病毒进行的实验显示,在相似的范围内复制受到抑制。在体外针对各种 Rhino 和地方性冠状病毒的 iota-卡拉胶数据显示出相似的 IC50 值,当含有 iota-卡拉胶的鼻喷雾剂证明可降低各种呼吸道病毒引起的普通感冒的严重程度和持续时间时,这些数据很容易转化为临床效果。因此,我们关于 SARS-CoV-2 刺突假型慢病毒和复制型 SARS-CoV-2 的体外数据表明,给予 iota-卡拉胶可能是预防或治疗 SARS-CoV-2 感染的有效和安全的方法。